Please ensure Javascript is enabled for purposes of website accessibility

Why the 21st Century Belongs to China

By Chuck Saletta – Updated Nov 10, 2016 at 7:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Growing R&D budgets, improving freedom, and low taxes.

The 19th century belonged to England, the 20th century belonged to the U.S., and the 21st century belongs to China. Invest accordingly. 

-- Warren Buffett

The 20th century was often called "the American Century." America's technological leadership, free market system, and low tax rates combined to unleash an unbeatable force of economic growth and unprecedented wealth. In the early part of the 21st century, unfortunately, the United States has done virtually everything in its power to destroy the very advantages that have made it such a powerful country.

How the U.S. lost its edge
There are many factors that play a role in America’s declining standing in the world economy, one of which is a corporate tax rate that is among the highest in the world. In 24 states, in fact, combined federal and state taxes are higher than those of any other country on Earth. Companies that feel comfortable with the economic and regulatory environments in another country may decide to relocate their talent and workforce there so they can keep more of what they earn.

Additionally, having failed to learn the lessons of Japan's failed financial bailout, the U.S. is now busy subsidizing its own failures, which is destroying its market economy. To cap off its problems, The Economist recently reported that "while corporate R&D in America and Europe grew by 1%-2% between 2001 and 2006, in China it soared 23%. China is now close to surpassing Japan in total research spending, from almost nothing a decade ago." This matters because R&D is correlated with productivity.

China gains from America's pain
As China continues along the path toward economic freedom and liberalization, its economic growth can very likely continue for quite some time. After all, China still has a lot of catching up to do just for the average citizen to reach parity with much of the developed world. And that doesn't even take into account the future benefits from all that cash being poured into R&D budgets and the lifestyle improvements that may arise from them.

Not only is China waking up to -- and rapidly adopting -- the market system, it is doing a far better job than the U.S. is at letting its successful entrepreneurs keep their cash. China’s new unified corporate tax rate is 25%, and the government grants many high-tech and export-oriented businesses additional exemptions.

With lower taxes, improving economic freedom, and strong Research and Development growth, China is setting itself up to take over the economic leadership position America is abandoning. It's no wonder that China's economy is still projected to grow 7.5% in 2009, even as the rest of the world teeters on the brink of a nasty recession.

An unbelievable opportunity
You might assume that Chinese companies would command a premium in the stock market. Amazingly enough, however, you can buy several Chinese companies more cheaply in terms of forward-looking earnings than you can American ones in similar business lines:

Industry

Country

Company

Forward P/E Ratio (Estimate)

Market Cap
(in Millions)

Electronic Equipment, Instruments, and Components

China

China Security and Surveilance
Technology
(NYSE:CSR)

4.8

$250

Electronic Equipment, Instruments, and Components

USA

Checkpoint Systems (NYSE:CKP)

8.0

$350

Health-care Equipment and Supplies

China

China Medical
Technologies
(NASDAQ:CMED)

6.3

$480

Health-care Equipment and Supplies

USA

Stryker (NYSE:SYK)

13.6

$16,880

Health-care Equipment and Supplies

USA

Becton, Dickinson, and
Company
(NYSE:BDX)

14.8

$17,550

Pharmaceuticals

China

Simcere Pharmaceutical (NYSE:SCR)

7.6

$420

Pharmaceuticals

USA

Bristol-Myers Squibb (NYSE:BMY)

11.0

$43,530

*Data from Capital IQ, a division of Standard & Poor’s.

So not only can you buy growth potential in these rapidly expanding Chinese markets, but you can do so more cheaply than buying larger American companies tethered to slower growth markets. That gives you a tremendous opportunity to buy into the long-term China growth story at an outrageous discount to those future expectations.

Are you ready to invest?
At Motley Fool Global Gains, we're not just following China from the sidelines. Instead, we're out there actively pursuing the best Chinese and other international companies while they trade at amazingly cheap valuations today. If you’d like, you can see our top stock ideas with a 30-day free guest pass to Global Gains.

Click here to learn more.

At the time of publication, Fool contributor Chuck Saletta did not own shares of any company mentioned in this article. The Fool owns shares of Stryker and has a disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Stryker Corporation Stock Quote
Stryker Corporation
SYK
$206.93 (-0.93%) $-1.95
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.71 (-0.81%) $0.58
Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$233.92 (-1.38%) $-3.27
Checkpoint Systems Inc. Stock Quote
Checkpoint Systems Inc.
CKP.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.